Kymera Therapeutics, Inc.

The momentum for this stock is not very good. Kymera Therapeutics, Inc. is a mediocre stock to choose.

News

Brokers Offer Predictions for Kymera Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:KYMR)

Ticker Report Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Leerink Partnrs issued their Q3 2024 EPS estimates for shares of Kymera Therapeutics in a research report issued on Monday...\n more…

Leerink Partnrs Comments on Kymera Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:KYMR)

Ticker Report Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Kymera Therapeutics in a research report...\n more…

Kymera Therapeutics (NASDAQ:KYMR) Raised to Strong-Buy at Leerink Partnrs

Zolmax Leerink Partnrs upgraded shares of Kymera Therapeutics (NASDAQ:KYMR - Free Report) to a strong-buy rating in a research note released on Monday morning, Zacks.com reports. Leerink Partnrs also issued...\n more…

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to "Strong-Buy" by Leerink Partnrs

Ticker Report Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) was upgraded by equities researchers at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Monday, Zacks.com reports...\n more…

Kymera Therapeutics (NASDAQ:KYMR) Receives Outperform Rating from Leerink Partners

Ticker Report Leerink Partners reissued their outperform rating on shares of Kymera Therapeutics (NASDAQ:KYMR - Free Report) in a research report report published on Monday morning, Marketbeat.com reports. They...\n more…

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Globe Newswire WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...\n more…